Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Relmada Therapeutics Inc 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 USA

www.relmada.com P: 786-629-1376

Description:

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 90,824
Enterprise Value, $K 86,734
Shares Outstanding, K 30,174
Annual Sales, $ 0 K
Annual Net Income, $ -98,790 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -21,830 K
EBIT, $ -98,540 K
EBITDA, $ -98,540 K
60-Month Beta 0.50
% of Insider Shareholders 18.00%
% of Institutional Shareholders 45.24%
Float, K 24,743
% Float 82.00%
Short Volume Ratio 0.31

Growth:

1-Year Return 15.77%
3-Year Return -91.21%
5-Year Return -55.99%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.72 on 05/08/24
Next Earnings Date 08/13/24
Earnings Per Share ttm -3.13
EPS Growth vs. Prev Qtr 14.29%
EPS Growth vs. Prev Year 17.24%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 09/30/19

RLMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -102.09%
Return-on-Assets % -91.30%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.26
Book Value/Share 2.39
Interest Coverage -1.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar